PeptiMed
Stage
Unattributed | AliveTotal Raised
$200KLast Raised
$200K | 7 yrs agoAbout PeptiMed
PeptiMed has invented a proprietary siRNA therapeutic drug that targets the EVI1 gene, called siEVI1, for treatment of advanced breast, prostate, lung, colon, ovarian, and skin cancer. The drug may be used initially as a second-line therapy, and advanced to first-line therapy once proven effective as a stand-alone treatment.
Missing: PeptiMed's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: PeptiMed's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing PeptiMed
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
PeptiMed is included in 4 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Advanced Materials
1,282 items
Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.
PeptiMed Patents
PeptiMed has filed 4 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/15/2015 | 10/30/2018 | Transcription factors, Molecular biology, Clusters of differentiation, RNA, Biotechnology | Grant |
Application Date | 6/15/2015 |
|---|---|
Grant Date | 10/30/2018 |
Title | |
Related Topics | Transcription factors, Molecular biology, Clusters of differentiation, RNA, Biotechnology |
Status | Grant |
Latest PeptiMed News
Jun 23, 2014
AAPS PharmSciTech: Dendrimer, Liposomes, Carbon Nanotubes and PLGA Nanoparticles: One Platform Assessment of Drug Delivery Potential The nanocomplex materials to be provided by PeptiMed will harbor motifs that bind to cell adhesion molecules on the surface of cancer cells and deliver an siRNA payload that silences the oncogene, EVI1. Initially, the NCL will assess the physical and chemical properties of the nanocomplexes followed by their purity and sterility in cell culture models. A second phase of testing for various modes of toxicity may be performed in animal models. “We are profoundly pleased to work with the NCL to further our understanding of PeptiMed nanomaterials,” stated Scott Schneider, CEO and co-founder of PeptiMed. “We are indeed fortunate to be able to rely on the expertise of the professionals at the NCL to get one step closer to the clinic.” PeptiMed co-founder Dr. Jeremy Heidel added, “The NCL has a strong track record in assisting biotech companies [as well as government and academic institutions] with evaluation and development of novel nanoparticle drug delivery systems. The comprehensive battery of measurements to be performed at the NCL will provide data and analytical methods that will help advance our nanoparticle technology toward the clinic.” ABOUT PEPTIMED The mission of PeptiMed is to discover and provide nucleotide-based therapies and delivery systems for nucleotide-based drugs with unprecedented potency in ameliorating late-stage cancer while avoiding debilitating side effects, thereby improving prognosis and quality of life for each patient. PeptiMed has patented the hELPTM nanoparticle delivery system for nucleotides. PeptiMed plans to begin first-in-human studies to determine maximum tolerated and efficacious doses of the EVIRNATM/hELPTM nanocomplex by the end of FY2015. This press release contains positive forward-looking statements concerning the therapeutic value of PeptiMed’s EVIRNATM/hELPTM nanocomplex. For further information please view the website www.peptimed.com or contactDr.Thomas Primiano, Chief Business Officer. PeptiMed
PeptiMed Frequently Asked Questions (FAQ)
What is PeptiMed's latest funding round?
PeptiMed's latest funding round is Unattributed.
How much did PeptiMed raise?
PeptiMed raised a total of $200K.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.